Soligenix Inc SNGX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1994-04-04 |
| Shares Out. | 14,820,000 |
| Website | soligenix.com/ ↗ |
| Phone | 13023513367 |
| Employees | 14 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$2.0M |
| Free Cash Flow | -$9.7M |
| Total Assets | $10.5M |
| Total Liabilities | $3.9M |
| Equity | $6.6M |
About Soligenix Inc
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
Soligenix Inc is a publicly traded company under the ticker symbol SNGX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-09-01)